membranoproliferative glomerulonephritis, X-linked

Summary

membranoproliferative glomerulonephritis, X-linked (MONDO:0010596) is a disease. A subtype of primary membranoproliferative glomerulonephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	membranoproliferative glomerulonephritis, X-linked
Mondo ID	MONDO:0010596
MeSH	C564423
OMIM	305800
UMLS	C1844501
MedGen	336706
GARD	0024739
Is cancer (heuristic)	no

Also known as: membranoproliferative glomerulonephritis, X-linked

Disease family

This is a subtype of primary membranoproliferative glomerulonephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › glomerulonephritis › primary membranoproliferative glomerulonephritis › membranoproliferative glomerulonephritis, X-linked

Related subtypes (2): immunoglobulin-mediated membranoproliferative glomerulonephritis, complement 3 glomerulopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.